Epigenomics of leukemia: From mechanisms to therapeutic applications

Epigenomics

Volumn 3, Issue 5, 2011, Pages 581-609

  Florean, Cristina ^a   Schnekenburger, Michael ^a   Grandjenette, Cindy ^a   Dicato, Mario ^a   Diederich, Marc ^a  

^a LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

Author keywords

cancer prevention; DNA methylation; epigenetic anticancer therapy; epigenetics; histone modifications; leukemia; miRNA

Indexed keywords

3 DEAZANEPLANOCIN A; 4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; ANACARDIC ACID; ANTINEOPLASTIC AGENT; AZACITIDINE; BELINOSTAT; BUTYRIC ACID; CURCUMIN; CYTARABINE; DAUNORUBICIN; ENTINOSTAT; ENZYME INHIBITOR; FLUDARABINE; GARCINOL; HISTONE DEACETYLASE INHIBITOR; IMATINIB; MOCETINOSTAT; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; QUINOLINE DERIVATIVE; RETINOIC ACID; ROMIDEPSIN; S ADENOSYLMETHIONINE; SINEFUNGIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CPG ISLAND; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; EPIGENETICS; EPILEPSY; GENE INACTIVATION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; LEUKEMIA; LEUKEMOGENESIS; MOLECULARLY TARGETED THERAPY; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RNA INTERFERENCE; TRANSCRIPTION REGULATION; TUMOR CELL DESTRUCTION; TUMOR SUPPRESSOR GENE;

DNA METHYLATION; EPIGENESIS, GENETIC; GENES, TUMOR SUPPRESSOR; HISTONE CODE; HUMANS; LEUKEMIA; MICRORNAS; MODELS, BIOLOGICAL; PHENOTYPE;

EID: 80054734934     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.11.73     Document Type: Review

References (281)

1. Dohner H, Stilgenbauer S, Fischer K, Schroder M, Bentz M, Lichter P. Diagnosis and monitoring of chromosome aberrations in hematological malignancies by fluorescence in situ hybridization. Stem Cells 13(Suppl. 3), 76-82 (1995).
2. Codony C, Crespo M, Abrisqueta P, Montserrat E, Bosch F. Gene expression profiling in chronic lymphocytic leukaemia. Best Pract. Res. Clin. Haematol. 22(2), 211-222 (2009).
3. Pekarsky Y, Zanesi N, Croce CM. Molecular basis of CLL. Semin. Cancer Biol. 20(6), 370-376 (2010).
4. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99(24), 15524-15529 (2002). (Pubitemid 35403967)
5. Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 112(8), 3322-3329 (2008).
6. Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. 120(7), 2254-2264 (2010).
7. Chen Y, Peng C, Sullivan C, Li D, Li S. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia 24(9), 1545-1554 (2010).
8. Mrûzek K, Harper DP, Aplan PD. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol. Oncol. Clin. North Am. 23(5), 991-1010 (2009).
9. Martens JHA, Stunnenberg HG. The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett. 584(12), 2662-2669 (2010).
10. Hatziapostolou M, Iliopoulos D. Epigenetic aberrations during oncogenesis. Cell Mol. Life Sci. 68(10), 1681-1702 (2011).
11. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 20(1), 1-13 (2006). (Pubitemid 43106714)
12. Chen J, Odenike O, Rowley JD. Leukaemogenesis: more than mutant genes. Nat. Rev. Cancer 10(1), 23-36 (2010).
13. Jones PA, Baylin SB. The epigenomics of cancer. Cell 128(4), 683-692 (2007). (Pubitemid 46273572)
14. Ting AH, Mcgarvey KM, Baylin SB. The cancer epigenome - components and functional correlates. Genes Dev. 20(23), 3215-3231 (2006). (Pubitemid 44904843)
15. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet. 16(Spec. No. 1), R50-R59 (2007). (Pubitemid 47241842)
16. Portela A, Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol. 28(10), 1057-1068 (2010).
17. Straussman R, Nejman D, Roberts D, et al. Developmental programming of CpG island methylation profiles in the human genome. Nat. Struct. Mol. Biol. 16(5), 564-571 (2009).
18. Barakat TS, Jonkers I, Monkhorst K, Gribnau J. X-changing information on X inactivation. Exp. Cell Res. 316(5), 679-687 (2010).
19. Wilkins JF. Genomic imprinting and methylation: epigenetic canalization and conflict. Trends Genet. 21(6), 356-365 (2005). (Pubitemid 40726393)
20. Goodier JL, Kazazian HH Jr. Retrotransposons revisited: the restraint and rehabilitation of parasites. Cell 135(1), 23-35 (2008).
21. Berger SL. The complex language of chromatin regulation during transcription. Nature 447(7143), 407-412 (2007). (Pubitemid 46816746)
22. Kouzarides T. Chromatin modifications and their function. Cell 128(4), 693-705 (2007). (Pubitemid 46273577)
23. Baylin SB. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. 2(Suppl. 1), S4-S11 (2005). (Pubitemid 43135229)
24. Issa JP, Zehnbauer BA, Kaufmann SH, Biel MA, Baylin SB. HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res. 57(9), 1678-1681 (1997). (Pubitemid 27199658)
25. Strathdee G, Holyoake TL, Sim A, et al. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin. Cancer Res. 13(17), 5048-5055 (2007). (Pubitemid 47502069)
26. Plass C, Yu F, Yu L, et al. Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene. Oncogene 18(20), 3159-3165 (1999). (Pubitemid 29261237)
27. Cameron EE, Baylin SB, Herman JG. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood 94(7), 2445-2451 (1999). (Pubitemid 29467693)
28. Wong IH, Ng MH, Huang DP, Lee JC. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 95(6), 1942-1949 (2000). (Pubitemid 30151630)
29. Asimakopoulos FA, Shteper PJ, Krichevsky S, et al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood 94(7), 2452-2460 (1999). (Pubitemid 29467694)
30. Mills KI, Guinn BA, Walsh VA, Burnett AK. Increasing methylation of the calcitonin gene during disease progression in sequential samples from CML patients. Leuk. Res. 20(9), 771-775 (1996). (Pubitemid 26388523)
31. Issa JP, Zehnbauer BA, Civin CI, et al. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res. 56(5), 973-977 (1996). (Pubitemid 26065388)
32. San Jose-Eneriz E, Agirre X, Jimenez-Velasco A, et al. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur. J. Cancer 45(10), 1877-1889 (2009).
33. Roman-Gomez J, Castillejo JA, Jimenez A, et al. 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 99(7), 2291-2296 (2002). (Pubitemid 34525411)
34. Roman J, Castillejo JA, Jimenez A, et al. Hypermethylation of the calcitonin gene in acute lymphoblastic leukaemia is associated with unfavourable clinical outcome. Br. J. Haematol. 113(2), 329-338 (2001). (Pubitemid 32523135)
35. Shteper PJ, Siegfried Z, Asimakopoulos FA, et al. ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL. Leukemia 15(4), 575-582 (2001). (Pubitemid 32266724)
36. Montserrat E. New prognostic markers in CLL. Hematol. Am. Soc. Hematol. Educ. Program 279-284 (2006).
37. Corcoran M, Parker A, Orchard J, et al. ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica 90(8), 1078-1088 (2005). (Pubitemid 41323507)
38. Raval A, Lucas DM, Matkovic JJ, et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J. Clin. Oncol. 23(17), 3877-3885 (2005). (Pubitemid 46218690)
39. Irving L, Mainou-Fowler T, Parker A, Ibbotson RE, Oscier DG, Strathdee G. Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia. Epigenetics 6(3), 300-306 (2011).
40. Strathdee G, Sim A, Parker A, Oscier D, Brown R. Promoter hypermethylation silences expression of the HoxA4 gene and correlates with IgVh mutational status in CLL. Leukemia 20(7), 1326-1329 (2006). (Pubitemid 43905849)
41. Mizuno S, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 97(5), 1172-1179 (2001). (Pubitemid 32183737)
42. Di Croce L, Raker VA, Corsaro M, et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295(5557), 1079-1082 (2002). (Pubitemid 34132239)
43. Narducci MG, Pescarmona E, Lazzeri C, et al. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res. 60(8), 2095-2100 (2000). (Pubitemid 30225165)
44. Yuille MR, Condie A, Stone EM, et al. TCL1 is activated by chromosomal rearrangement or by hypomethylation. Genes Chromosomes Cancer 30(4), 336-341 (2001). (Pubitemid 32216324)
45. Carney DA, Wierda WG. Genetics and molecular biology of chronic lymphocytic leukemia. Curr. Treat. Options Oncol. 6(3), 215-225 (2005). (Pubitemid 40945451)
46. Melki JR, Clark SJ. DNA methylation changes in leukaemia. Semin. Cancer Biol. 12(5), 347-357 (2002).
47. Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24(48), 7213-7223 (2005). (Pubitemid 41679283)
48. Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. Haematologica 92(2), 153-162 (2007).
49. Rogers SL, Zhao Y, Jiang X, Eaves CJ, Mager DL, Rouhi A. Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia. Mol. Cancer 9, 41 (2010).
50. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363(25), 2424-2433 (2010).
51. Shah MY, Licht JD. DNMT3A mutations in acute myeloid leukemia. Nat. Genet. 43(4), 289-290 (2011).
52. Yamashita Y, Yuan J, Suetake I, et al. Array-based genomic resequencing of human leukemia. Oncogene 29(25), 3723-3731 (2010).
53. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6), 553-567 (2010).
54. Brecqueville M, Cervera N, Gelsi-Boyer V, et al. Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes. Blood Cancer J. 1, 1-2 (2011).
55. Watt PM, Kumar R, Kees UR. Promoter demethylation accompanies reactivation of the HOX11 proto-oncogene in leukemia. Genes Chromosomes Cancer 29(4), 371-377 (2000).
56. Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin. Cancer Res. 15(12), 3918-3926 (2009).
57. Grovdal M, Karimi M, Khan R, et al. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br. J. Haematol. 150(3), 293-302 (2010).
58. Khan R, Schmidt-Mende J, Karimi M, et al. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp. Hematol. 36(2), 149-157 (2008).
59. Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, Tamm I. Induction of gene expression by 5-aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia 19(1), 103-111 (2005). (Pubitemid 40090084)
60. Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP. 5-aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64(4), 922-929 (1984).
61. Yang Q, Shan L, Yoshimura G, et al. 5-aza-2′- deoxycytidine induces retinoic acid receptor b 2 demethylation, cell cycle arrest and growth inhibition in breast carcinoma cells. Anti Cancer Res. 22(5), 2753-2756 (2002). (Pubitemid 36069308)
62. Schnekenburger M, Grandjenette C, Ghelfi J, et al. Sustained exposure to the DNA demethylating agent, 2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy. Biochem. Pharmacol. 81(3), 364-378 (2011).
63. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 6(11), 838-849 (2005). (Pubitemid 41568733)
64. Di Gennaro E, Bruzzese F, Caraglia M, Abruzzese A, Budillon A. Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids 26(4), 435-441 (2004). (Pubitemid 39093148)
65. Hodawadekar SC, Marmorstein R. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene 26(37), 5528-5540 (2007). (Pubitemid 47255933)
66. Close P, Creppe C, Gillard M, et al. The emerging role of lysine acetylation of non-nuclear proteins. Cell Mol. Life Sci. 67(8), 1255-1264 (2010).
67. Hildmann C, Riester D, Schwienhorst A. Histone deacetylases - an important class of cellular regulators with a variety of functions. Appl. Microbiol. Biotechnol. 75(3), 487-497 (2007). (Pubitemid 46776553)
68. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkuhler C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res. 17(3), 195-211 (2007). (Pubitemid 46438722)
69. Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 324(20), 1385-1393 (1991).
70. Minucci S, Cioce M, Maccarana M, Pelicci PG. The APL-associated fusion proteins. Haematologica 84(Suppl. EHA-4), 70-71 (1999).
71. Lin RJ, Evans RM. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol. Cell 5(5), 821-830 (2000).
72. Minucci S, Nervi C, Lo Coco F, Pelicci PG. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20(24), 3110-3115 (2001). (Pubitemid 32553566)
73. Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl Cancer. Inst. 90(21), 1621-1625 (1998). (Pubitemid 28523436)
74. He LZ, Tolentino T, Grayson P, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108(9), 1321-1330 (2001). (Pubitemid 33107760)
75. Tickenbrock L, Klein HU, Trento C, et al. Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival. Leuk. Res. 35(5), 620-625 (2011).
76. Martens JH, Brinkman AB, Simmer F, et al. PML-RARa/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell 17(2), 173-185 (2010).
77. Bradbury CA, Khanim FL, Hayden R, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19(10), 1751-1759 (2005). (Pubitemid 41486152)
78. Moreno DA, Scrideli CA, Cortez MA, et al. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 150(6), 665-673 (2010).
79. Advani AS, Gibson SE, Douglas E, et al. Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients. BMC Cancer 10, 387 (2010).
80. Di Croce L. Chromatin modifying activity of leukaemia associated fusion proteins. Hum. Mol. Genet. 14(Spec. No. 1), R77-R84 (2005). (Pubitemid 40542623)
81. Wang GG, Allis CD, Chi P. Chromatin remodeling and cancer, Part I: Covalent histone modifications. Trends Mol. Med. 13(9), 363-372 (2007). (Pubitemid 47385381)
82. Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471(7337), 235-239 (2011).
83. Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat. Rev. Drug Discov. 8(9), 724-732 (2009).
84. Tsukada Y, Fang J, Erdjument-Bromage H, et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature 439(7078), 811-816 (2006). (Pubitemid 43255695)
85. Cloos PA, Christensen J, Agger K, Helin K. Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev. 22(9), 1115-1140 (2008). (Pubitemid 351656572)
86. Hublitz P, Albert M, Peters AH. Mechanisms of transcriptional repression by histone lysine methylation. Int. J. Dev. Biol. 53(2-3), 335-354 (2009).
87. Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. Cancer genetics of epigenetic genes. Hum. Mol. Genet. 16(Spec. No. 1), R28-R49 (2007). (Pubitemid 47241841)
88. Albert M, Helin K. Histone methyltransferases in cancer. Semin. Cell. Dev. Biol. 21(2), 209-220 (2010).
89. Hess JL. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol. Med. 10(10), 500-507 (2004). (Pubitemid 39303623)
90. Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell 121(2), 167-178 (2005). (Pubitemid 40546386)
91. Krivtsov AV, Feng Z, Lemieux ME, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14(5), 355-368 (2008).
92. Chang MJ, Wu H, Achille NJ, et al. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 70(24), 10234-10242 (2010).
93. Nebral K, Konig M, Schmidt HH, et al. Screening for NUP98 rearrangements in hematopoietic malignancies by fluorescence in situ hybridization. Haematologica 90(6), 746-752 (2005). (Pubitemid 40897216)
94. Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat. Cell Biol. 9(7), 804-812 (2007). (Pubitemid 47019467)
95. Rosati R, La Starza R, Veronese A, et al. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11) (p11. 2;p15). Blood 99(10), 3857-3860 (2002). (Pubitemid 34534564)
96. Simon JA. Chromatin compaction at Hox loci: a polycomb tale beyond histone tails. Mol. Cell 38(3), 321-322 (2010).
97. Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 647(1-2), 21-29 (2008).
98. Sasaki D, Imaizumi Y, Hasegawa H, et al. Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica 96(5), 712-719 (2011).
99. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42(8), 722-726 (2010).
100. Marteau JB, Rigaud O, Brugat T, et al. Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELB in an aggressive subset of chronic lymphocytic leukemia in males. BMC Med. Genomics 3, 53 (2010).
101. Varier RA, Timmers HT. Histone lysine methylation and demethylation pathways in cancer. Biochim. Biophys. Acta 1815(1), 75-89 (2011).
102. He J, Nguyen AT, Zhang Y. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood 117(14), 3869-3880 (2011).
103. Hu X, Li X, Valverde K, et al. LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis. Proc. Natl Acad. Sci. USA 106(25), 10141-10146 (2009).
104. Altucci L, Clarke N, Nebbioso A, Scognamiglio A, Gronemeyer H. Acute myeloid leukemia: therapeutic impact of epigenetic drugs. Int. J. Biochem. Cell Biol. 37(9), 1752-1762 (2005). (Pubitemid 40961660)
105. Leone G, DAlo F, Zardo G, Voso MT, Nervi C. Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. Curr. Med. Chem. 15(13), 1274-1287 (2008). (Pubitemid 351997797)
106. Marks PA. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim. Biophys. Acta 1799(10-12), 717-725 (2010).
107. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res. 15(12), 3958-3969 (2009).
108. Quintas-Cardama A, Santos FP, Garcia- Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 25(2), 226-235 (2011).
109. Zain J, OConnor OA. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest. New Drugs 28(Suppl. 1), S58-S78 (2010).
110. Mercurio C, Minucci S, Pelicci PG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol. Res. 62(1), 18-34 (2010).
111. Gore SD, Weng LJ, Zhai S, et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 7(8), 2330-2339 (2001). (Pubitemid 32751632)
112. Batova A, Shao LE, Diccianni MB, et al. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood 100(9), 3319-3324 (2002). (Pubitemid 35217083)
113. Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol. pii, 479364 (2010).
114. Handoko KB, Souverein PC, Van Staa TP, et al. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia 47(7), 1232-1236 (2006). (Pubitemid 44086760)
115. Chateauvieux S, Eifes S, Morceau F, et al. Valproic acid perturbs hematopoietic homeostasis by inhibition of erythroid differentiation and activation of the myelo-monocytic pathway. Biochem. Pharmacol. 81(4), 498-509 (2011).
116. Gao S, Mobley A, Miller C, Boklan J, Chandra J. Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. Leuk. Res. 32(5), 771-780 (2008). (Pubitemid 351323931)
117. Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109(7), 2781-2790 (2007). (Pubitemid 46482071)
118. Blum KA, Advani A, Fernandez L, et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br. J. Haematol. 147(4), 507-514 (2009).
119. Inoue S, Mai A, Dyer MJ, Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 66(13), 6785-6792 (2006). (Pubitemid 44085638)
120. Vernarecci S, Tosi F, Filetici P. Tuning acetylated chromatin with HAT inhibitors: a novel tool for therapy. Epigenetics 5(2), 105-111 (2010).
121. Bowers EM, Yan G, Mukherjee C, et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 17(5), 471-482 (2010).
122. Ott M, Verdin E. HAT trick: p300, small molecule, inhibitor. Chem. Biol. 17(5), 417-418 (2010).
123. Mori S, Iwase K, Iwanami N, Tanaka Y, Kagechika H, Hirano T. Development of novel bisubstrate-type inhibitors of histone methyltransferase SET7/9. Bioorg. Med. Chem. 18(23), 8158-8166 (2010).
124. Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat. Chem. Biol. 1(3), 143-145 (2005).
125. Iwasa E, Hamashima Y, Fujishiro S, et al. Total synthesis of (+)-chaetocin and its analogues: their histone methyltransferase G9a inhibitory activity. J. Am. Chem. Soc. 132(12), 4078-4079 (2010).
126. Lakshmikuttyamma A, Scott SA, Decoteau JF, Geyer CR. Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition. Oncogene 29(4), 576-588 (2010).
127. Kubicek S, OSullivan RJ, August EM, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell. 25(3), 473-481 (2007). (Pubitemid 46206139)
128. Chang Y, Zhang X, Horton JR, et al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat. Struct. Mol. Biol. 16(3), 312-317 (2009).
129. Chang Y, Ganesh T, Horton JR, et al. Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases. J. Mol. Biol. 400(1), 1-7 (2010).
130. Liu F, Chen X, Allali-Hassani A, et al. Discovery of a 2,4-diamino-7- aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J. Med. Chem. 52(24), 7950-7953 (2009).
131. Liu F, Chen X, Allali-Hassani A, et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J. Med. Chem. 53(15), 5844-5857 (2010).
132. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21(9), 1050-1063 (2007). (Pubitemid 46686474)
133. Fiskus W, Wang Y, Sreekumar A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114(13), 2733-2743 (2009).
134. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem. Biol. 13(6), 563-567 (2006).
135. Schmidt DM, Mccafferty DG. Trans-2-phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 46(14), 4408-4416 (2007). (Pubitemid 46559406)
136. Mimasu S, Umezawa N, Sato S, Higuchi T, Umehara T, Yokoyama S. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1. Biochemistry 49(30), 6494-6503 (2010).
137. Binda C, Valente S, Romanenghi M, et al. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J. Am. Chem. Soc. 132(19 6827-6833 (2010).
138. Szewczuk LM, Culhane JC, Yang M, Majumdar A, Yu H, Cole PA. Mechanistic analysis of a suicide inactivator of histone demethylase LSD1. Biochemistry 46(23), 6892-6902 (2007). (Pubitemid 46906418)
139. Ueda R, Suzuki T, Mino K, et al. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J. Am. Chem. Soc. 131(48), 17536-17537 (2009).
140. Sharma SK, Wu Y, Steinbergs N, et al. (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. J. Med. Chem. 53(14), 5197-5212 (2010).
141. Hou H, Yu H. Structural insights into histone lysine demethylation. Curr. Opin. Struct. Biol. 20(6), 739-748 (2010).
142. Hamada S, Suzuki T, Mino K, et al. Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors. J. Med. Chem. 53(15), 5629-5638 (2010).
143. King ON, Li XS, Sakurai M, et al. Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. PLoS ONE 5(11), e15535 (2010).
144. Rose NR, Woon EC, Kingham GL, et al. Selective inhibitors of the JMJD2 histone demethylases: combined nondenaturing mass spectrometric screening and crystallographic approaches. J. Med. Chem. 53(4), 1810-1818 (2010).
145. Winter J, Diederichs S. MicroRNA biogenesis and cancer. Methods Mol. Biol. 676, 3-22 (2011).
146. Kusenda B, Mraz M, Mayer J, Pospisilova S. MicroRNA biogenesis, functionality and cancer relevance. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 150(2), 205-215 (2006).
147. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res. 65(9), 3509-3512 (2005). (Pubitemid 40616320)
148. Cortez MA, Ivan C, Zhou P, Wu X, Ivan M, Calin GA. MicroRNAs in cancer: from bench to bedside. Adv. Cancer Res. 108, 113-157 (2010).
149. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev. Cell 11(4), 441-450 (2006). (Pubitemid 44430905)
150. Ambros V. The functions of animal microRNAs. Nature 431(7006), 350-355 (2004). (Pubitemid 39265675)
151. Barbarotto E, Schmittgen TD, Calin GA. MicroRNAs and cancer: profile, profile, profile. Int. J. Cancer 122(5), 969-977 (2008). (Pubitemid 351213993)
152. Zhao H, Wang D, Du W, Gu D, Yang R. MicroRNA and leukemia: tiny molecule, great function. Crit. Rev. Oncol. Hematol. 74(3), 149-155 (2010).
153. Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J. The role of microRNAs in normal and malignant hematopoiesis. Eur. J. Haematol. 84(1), 1-16 (2010).
154. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 102(39), 13944-13949 (2005). (Pubitemid 41377683)
155. Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353(17), 1793-1801 (2005). (Pubitemid 41549891)
156. Pekarsky Y, Santanam U, Cimmino A, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 66(24), 11590-11593 (2006). (Pubitemid 46094168)
157. Fulci V, Chiaretti S, Goldoni M, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 109(11), 4944-4951 (2007). (Pubitemid 46827793)
158. Zhu DX, Miao KR, Fang C, et al. Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia. Leuk. Res. 35(6), 730-734 (2010).
159. Ricci F, Tedeschi A, Morra E, Montillo M. Fludarabine in the treatment of chronic lymphocytic leukemia: a review. Ther. Clin. Risk Manag. 5(1), 187-207 (2009).
160. Moussay E, Palissot V, Vallar L, et al. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol. Cancer 9, 115 (2010).
161. Ferracin M, Zagatti B, Rizzotto L, et al. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol. Cancer 9, 123 (2010).
162. Zenz T, Mohr J, Eldering E, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 113(16), 3801-3808 (2009).
163. Mraz M, Malinova K, Kotaskova J, et al. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 23(6), 1159-1163 (2009).
164. Asslaber D, Pinon JD, Seyfried I, et al. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood 115(21), 4191-4197 (2010).
165. Rossi S, Shimizu M, Barbarotto E, et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 116(6), 945-952 (2010).
166. Stamatopoulos B, Meuleman N, Haibe-Kains B, et al. MicroRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 113(21), 5237-5245 (2009).
167. Venturini L, Battmer K, Castoldi M, et al. Expression of the miR-17-92
168. Bueno MJ, Perez de Castro I, Gomez de Cedron M, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13(6), 496-506 (2008). (Pubitemid 351763902)
169. Flamant S, Ritchie W, Guilhot J, et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 95(8), 1325-1333 (2010).
170. San Jose-Eneriz E, Roman-Gomez J, Jimenez-Velasco A, et al. MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol. Cancer 8, 69 (2009).
171. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 111(10), 5078-5085 (2008).
172. Li Z, Lu J, Sun M, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc. Natl Acad. Sci. USA 105(40), 15535-15540 (2008).
173. Garzon R, Garofalo M, Martelli MP, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc. Natl Acad. Sci. USA 105(10), 3945-3950 (2008). (Pubitemid 351723504)
174. Isken F, Steffen B, Merk S, et al. Identification of acute myeloid leukaemia associated microRNA expression patterns. Br. J. Haematol. 140(2), 153-161 (2008). (Pubitemid 350265050)
175. Brioschi M, Fischer J, Cairoli R, et al. Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits. Neoplasia 12(11), 866-876 (2010).
176. Pulikkan JA, Peramangalam PS, Dengler V, et al. C/EBPa regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood 116(25), 5638-5649 (2010).
177. Marcucci G, Maharry K, Radmacher MD, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a cancer and leukemia group B study. J. Clin. Oncol. 26(31), 5078-5087 (2008).
178. Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358(18), 1919-1928 (2008). (Pubitemid 351620112)
179. Debernardi S, Skoulakis S, Molloy G, Chaplin T, Dixon-McIver A, Young BD. MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia 21(5), 912-916 (2007). (Pubitemid 46672066)
180. Vazquez I, Maicas M, Marcotegui N, et al. Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia. Proc. Natl Acad. Sci. USA 107(44), E167-168; author reply E169-E170 (2010).
181. Mi S, Lu J, Sun M, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc. Natl Acad. Sci. USA 104(50), 19971-19976 (2007).
182. Schotte D, Chau JC, Sylvester G, et al. Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia 23(2), 313-322 (2009).
183. Schotte D, De Menezes RX, Akbari Moqadam F, et al. MicroRNAs characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 96(5), 703-711 (2011).
184. Garzon R, Pichiorri F, Palumbo T, et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 26(28), 4148-4157 (2007). (Pubitemid 46920170)
185. Hammond SM. MicroRNA therapeutics: a new niche for antisense nucleic acids. Trends Mol. Med. 12(3), 99-101 (2006).
186. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327(5962), 198-201 (2010).
187. Gao SM, Chen C, Wu J, et al. Synergistic apoptosis induction in leukemic cells by miR-15a/16-11 and arsenic trioxide. Biochem. Biophys. Res. Commun. 403(2), 203-208 (2010).
188. Gu J, Zhu X, Li Y, et al. miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Med. Oncol. 28(1), 211-218 (2011).
189. Hu H, Li Y, Gu J, et al. Antisense oligonucleotide against miR-21 inhibits migration and induces apoptosis in leukemic K562 cells. Leuk. Lymphoma 51(4), 694-701 (2010).
190. Roman-Gomez J, Agirre X, Jimenez-Velasco A, et al. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J. Clin. Oncol. 27(8), 1316-1322 (2009).
191. Folmer F, Orlikova B, Schnekenburger M, Dicato M, Diederich M. Naturally occurring regulators of histone acetylation/deacetylation. Curr. Nutr. Food Sci. 6, 78-99 (2010).
192. Link A, Balaguer F, Goel A. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem. Pharmacol. 80(12), 1771-1792 (2010).
193. vel Szic KS, Ndlovu MN, Haegeman G, Vanden Berghe W. Nature or nurture: let food be your epigenetic medicine in chronic inflammatory disorders. Biochem. Pharmacol. 80(12), 1816-1832 (2010).
194. Garcia-Manero G, Daniel J, Smith TL, et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin. Cancer Res. 8(7), 2217-2224 (2002). (Pubitemid 34753593)
195. Taylor KH, Pena-Hernandez KE, Davis JW, et al. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res. 67(6), 2617-2625 (2007). (Pubitemid 46548948)
196. Issa JP, Kantarjian H, Mohan A, et al. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood 93(6), 2075-2080 (1999). (Pubitemid 29128511)
197. Rahmatpanah FB, Carstens S, Hooshmand SI, et al. Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. Epigenomics 1(1), 39-61 (2009).
198. Kuang SQ, Tong WG, Yang H, et al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 22(8), 1529-1538 (2008).
199. Mulero-Navarro S, Carvajal-Gonzalez JM, Herranz M, et al. The dioxin receptor is silenced by promoter hypermethylation in human acute lymphoblastic leukemia through inhibition of Sp1 binding. Carcinogenesis 27(5), 1099-1104 (2006).
200. Dunwell T, Hesson L, Rauch TA, et al. A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. Mol. Cancer 9, 44 (2010).
201. Taniguchi H, Fernandez AF, Setien F, et al. Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. Cancer Res. 69(21), 8447-8454 (2009).
202. Murai M, Toyota M, Satoh A, et al. Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. Br. J. Cancer 92(6), 1165-1172 (2005). (Pubitemid 40546685)
203. Scardocci A, Guidi F, DAlo F, et al. Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. Br. J. Cancer 95(8), 1108-1113 (2006). (Pubitemid 44606840)
204. Ritter M, de Kant E, Huhn D, Neubauer A. Detection of DNA methylation in the calcitonin gene in human leukemias using differential polymerase chain reaction. Leukemia 9(5), 915-921 (1995).
205. Garcia-Manero G, Yang H, Kuang SQ, OBrien S, Thomas D, Kantarjian H. Epigenetics of acute lymphocytic leukemia. Semin. Hematol. 46(1), 24-32 (2009).
206. Takahashi T, Shivapurkar N, Reddy J, et al. DNA methylation profiles of lymphoid and hematopoietic malignancies. Clin. Cancer Res. 10(9), 2928-2935 (2004). (Pubitemid 38619667)
207. Matsushita C, Yang Y, Takeuchi S, et al. Aberrant methylation in promoter-associated CpG islands of multiple genes in relapsed childhood acute lymphoblastic leukemia. Oncol Rep. 12(1), 97-99 (2004).
208. Ekmekci CG, Gutierrez MI, Siraj AK, Ozbek U, Bhatia K. Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am. J. Hematol. 77(3), 233-240 (2004). (Pubitemid 39430701)
209. San Jose-Eneriz E, Agirre X, Roman-Gomez J, et al. Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter. Br. J. Haematol. 134(2), 137-144 (2006). (Pubitemid 43893905)
210. Wang YL, Qian J, Lin J, et al. Methylation status of DDIT3 gene in chronic myeloid leukemia. J. Exp. Clin. Cancer Res. 29, 54 (2010).
211. Roman-Gomez J, Cordeu L, Agirre X, et al. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 109(8), 3462-3469 (2007). (Pubitemid 46572536)
212. Yao J, Huang Q, Zhang XB, Fu WL. Promoter CpG methylation of oestrogen receptors in leukaemia. Biosci. Rep. 29(4), 211-216 (2009).
213. Uhm KO, Lee ES, Lee YM, et al. Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia. J. Korean Med. Sci. 24(3), 493-497 (2009).
214. Hoshino K, Quintas-Cardama A, Yang H, Sanchez-Gonzalez B, Garcia-Manero G. Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia. Leukemia 21(5), 906-911 (2007). (Pubitemid 46672065)
215. Pallasch CP, Patz M, Park YJ, et al. miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood 114(15), 3255-3264 (2009).
216. Chim CS, Wong KY, Leung CY, et al. Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. J. Cell Mol. Med. DOI: 0.1111/j.1582- 4934.2011.01274.x. (2011) (Epub ahead of print).
217. Kroeger H, Jelinek J, Estecio MR, et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 112(4), 1366-1373 (2008).
218. Montiel-Duarte C, Cordeu L, Agirre X, et al. Resistance to imatinib mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Leuk. Res. 32(5), 709-716 (2008). (Pubitemid 351330173)
219. Della Peruta M, Martinelli G, Moratti E, et al. Protein tyrosine phosphatase receptor type {g} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. Cancer Res. 70(21), 8896-8906 (2010).
220. Hesson LB, Dunwell TL, Cooper WN, et al. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol. Cancer 8, 42 (2009).
221. Bechter OE, Eisterer W, Dlaska M, Kuhr T, Thaler J. CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia. Exp. Hematol. 30(1), 26-33 (2002). (Pubitemid 34059214)
222. Chantepie SP, Vaur D, Grunau C, et al. ZAP-70 intron1 DNA methylation status: determination by pyrosequencing in B chronic lymphocytic leukemia. Leuk. Res. 34(6), 800-808 (2010).
223. Marton S, Garcia MR, Robello C, et al. Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 22(2), 330-338 (2008). (Pubitemid 351250538)
224. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci. 98(12), 1914-1920 (2007). (Pubitemid 350002197)
225. Frenquelli M, Muzio M, Scielzo C, et al. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood 115(19), 3949-3959 (2010).
226. Cardinaud B, Moreilhon C, Marcet B, et al. miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic lymphocytic leukaemia? Leukemia 23(11), 2174-2177 (2009).
227. Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol. Cancer Res. 6(12), 1830-1840 (2008).
228. Chapiro E, Russell LJ, Struski S, et al. A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia. Leukemia 24(7), 1362-1364 (2010).
229. Bousquet M, Harris MH, Zhou B, Lodish HF. MicroRNA miR-125b causes leukemia. Proc. Natl Acad. Sci. USA 107(50), 21558-21563 (2010).
230. Tassano E, Acquila M, Tavella E, Micalizzi C, Panarello C, Morerio C. MicroRNA-125b-1 and BLID upregulation resulting from a novel IGH translocation in childhood B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer 49(8), 682-687 (2010).
231. Zanette DL, Rivadavia F, Molfetta GA, et al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz. J. Med. Biol. Res. 40(11), 1435-1440 (2007). (Pubitemid 350302855)
232. Bhatia S, Kaul D, Varma N. Potential tumor suppressive function of miR-196b in B-cell lineage acute lymphoblastic leukemia. Mol. Cell Biochem. 340(1-2), 97-106 (2010).
233. Careccia S, Mainardi S, Pelosi A, et al. A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene 28(45), 4034-4040 (2009).
234. Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111(6), 3183-3189 (2008).
235. Li Z, Luo RT, Mi S, et al. Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res. 69(3), 1109-1116 (2009).
236. Mi S, Li Z, Chen P, et al. Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc. Natl Acad. Sci. USA 107(8), 3710-3715 (2010).
237. Wong P, Iwasaki M, Somervaille TC, et al. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res. 70(9), 3833-3842 (2010).
238. Gao XN, Lin J, Li YH, et al. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene 30(31), 3416-3428 (2011).
239. Popovic R, Riesbeck LE, Velu CS, et al. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 113(14), 3314-3322 (2009).
240. Ramsingh G, Koboldt DC, Trissal M, et al. Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood 116(24), 5316-5326 (2010).
241. Liu S, Wu LC, Pang J, et al. Sp1/NFkB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 17(4), 333-347 (2010).
242. Paluszczak J, Krajka-Kuzniak V, Baer- Dubowska W. The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicol. Lett. 192(2), 119-125 (2010).
243. Li Y, Vandenboom TG 2nd, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 69(16), 6704-6712 (2009).
244. Wang LG, Liu XM, Fang Y, et al. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int. J. Oncol. 33(2), 375-380 (2008).
245. Nair S, Hebbar V, Shen G, et al. Synergistic effects of a combination of dietary factors sulforaphane and (-) epigallocatechin-3- gallate in HT-29 AP-1 human colon carcinoma cells. Pharm. Res. 25(2), 387-399 (2008). (Pubitemid 351257971)
246. Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp. Biol. Med. (Maywood) 232(2), 227-234 (2007). (Pubitemid 46203291)
247. Li Y, Li X, Guo B. Chemopreventive agent 3,3′-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res. 70(2), 646-654 (2010).
248. Mai A, Rotili D, Tarantino D, et al. Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. J. Med. Chem. 49(23), 6897-6907 (2006). (Pubitemid 44749755)
249. Balasubramanyam K, Swaminathan V, Ranganathan A, Kundu TK. Small molecule modulators of histone acetyltransferase p300. J. Biol. Chem. 278(21), 19134-19140 (2003). (Pubitemid 36799302)
250. Eliseeva ED, Valkov V, Jung M, Jung MO. Characterization of novel inhibitors of histone acetyltransferases. Mol. Cancer Ther. 6(9), 2391-2398 (2007). (Pubitemid 47480404)
251. Sung B, Pandey MK, Ahn KS, et al. Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-kBa kinase, leading to potentiation of apoptosis. Blood 111(10), 4880-4891 (2008).
252. Bora-Tatar G, Dayangac-Erden D, Demir AS, Dalkara S, Yelekci K, Erdem-Yurter H. Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: activity and docking studies. Bioorg. Med. Chem. 17(14), 5219-5228 (2009).
253. Waldecker M, Kautenburger T, Daumann H, Busch C, Schrenk D. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J. Nutr. Biochem. 19(9), 587-593 (2008).
254. Tan S, Wang C, Lu C, et al. Quercetin is able to demethylate the p16INK4a gene promoter. Chemotherapy 55(1), 6-10 (2009).
255. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425(6954), 191-196 (2003). (Pubitemid 37150899)
256. Wood JG, Rogina B, Lavu S, et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430(7000), 686-689 (2004). (Pubitemid 39061685)
257. Ruiz PA, Braune A, Holzlwimmer G, Quintanilla-Fend L, Haller D. Quercetin inhibits TNF-induced NF-kB transcription factor recruitment to proinflammatory gene promoters in murine intestinal epithelial cells. J. Nutr. 137(5), 1208-1215 (2007). (Pubitemid 46701913)
258. Lee WJ, Zhu BT. Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis 27(2), 269-277 (2006). (Pubitemid 43159879)
259. Arif M, Pradhan SK, Thanuja GR, et al. Mechanism of p300 specific histone acetyltransferase inhibition by small molecules. J. Med. Chem. 52(2), 267-277 (2009).
260. Nian H, Delage B, Pinto JT, Dashwood RH. Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis 29(9), 1816-1824 (2008).
261. Lea MA, Rasheed M, Randolph VM, Khan F, Shareef A, Desbordes C. Induction of histone acetylation and inhibition of growth of mouse erythroleukemia cells by S-allylmercaptocysteine. Nutr. Cancer 43(1), 90-102 (2002). (Pubitemid 35387261)
262. Druesne N, Pagniez A, Mayeur C, et al. Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis 25(7), 1227-1236 (2004). (Pubitemid 38968051)
263. Gracia-Sancho J, Villarreal G Jr, Zhang Y, Garcia-Cardena G. Activation of SIRT1 by resveratrol induces KLF2 expression conferring an endothelial vasoprotective phenotype. Cardiovasc. Res. 85(3), 514-519 (2010).
264. Kaeberlein M, Mcdonagh T, Heltweg B, et al. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 280(17), 17038-17045 (2005). (Pubitemid 41389166)
265. Yang J, Kong X, Martins-Santos ME, et al. Activation of SIRT1 by resveratrol represses transcription of the gene for the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) by deacetylating hepatic nuclear factor 4a. J. Biol. Chem. 284(40), 27042-27053 (2009).
266. Boily G, He XH, Pearce B, Jardine K, Mcburney MW. SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene 28(32), 2882-2893 (2009).
267. Tsao AS, Liu D, Martin J, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev. Res. (Phila.) 2(11), 931-941 (2009).
268. Choi KC, Jung MG, Lee YH, et al. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res. 69(2), 583-592 (2009).
269. Balasubramanian S, Adhikary G, Eckert RL. The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival. Carcinogenesis 31(3), 496-503 (2010).
270. Tsang WP, Kwok TT. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J. Nutr. Biochem. 21(2), 140-146 (2010).
271. Fang MZ, Chen D, Sun Y, Jin Z, Christman JK, Yang CS. Reversal of hypermethylation and reactivation of p16INK4a, RARb, and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res. 11(19 Pt 1), 7033-7041 (2005). (Pubitemid 41428763)
272. Majid S, Dar AA, Ahmad AE, et al. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis 30(4), 662-670 (2009).
273. Tang WY, Newbold R, Mardilovich K, et al. Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. Endocrinology 149(12), 5922-5931 (2008).
274. King-Batoon A, Leszczynska JM, Klein CB. Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environ. Mol. Mutagen. 49(1), 36-45 (2008). (Pubitemid 351293011)
275. Liu Z, Xie Z, Jones W, et al. Curcumin is a potent DNA hypomethylation agent. Bioorg. Med. Chem. Lett. 19(3), 706-709 (2009).
276. Chen Y, Shu W, Chen W, Wu Q, Liu H, Cui G. Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kB and Notch 1 in Raji cells. Basic Clin. Pharmacol. Toxicol. 101(6), 427-433 (2007). (Pubitemid 350135350)
277. Marcu MG, Jung YJ, Lee S, et al. Curcumin is an inhibitor of p300 histone acetylatransferase. Med. Chem. 2(2), 169-174 (2006). (Pubitemid 44083157)
278. Chiu J, Khan ZA, Farhangkhoee H, Chakrabarti S. Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-kB. Nutrition 25(9), 964-972 (2009).
279. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol. Cancer. Ther. 7(3), 464-473 (2008). (Pubitemid 351482129)
280. Ali S, Ahmad A, Banerjee S, et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 70(9), 3606-3617 (2010).
281. Clinical Trial Database www.clinicaltrial.gov